Package Leaflet: Information for the User
BEXIDERMIL 100 mg/g cream
Triethanolamine salicylate
Read the entire package leaflet carefully before starting to use thismedicationbecause it contains important information for you.
Follow the administration instructions of the medication contained in this package leaflet or as indicated by your doctor or pharmacist.
Contents of the package leaflet:
Bexidermil is a cream for cutaneous use.
Triethanolamine salicylate, the active ingredient of this medication, belongs to the group of cutaneous preparations for joint and muscle pain.
This medication is indicated in adults and adolescents from 12 years of age for the local symptomatic relief of muscle and joint pain such as:
You should consult a doctor if it worsens or does not improve after 7 days of treatment.
Do not use Bexidermil 100 mg/g cream
Warnings and precautions
Consult your doctor or pharmacist before starting to use Bexidermil 100 mg/g cream.
Before applying Bexidermil, you should consider:
Children
This medication should not be used in children under 12 years of age.
Use of other medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Do not apply other similar products to the same area.
Inform your doctor if you are being treated with oral anticoagulants (such as acenocoumarol and warfarin). Your doctor will decide if you can use the medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnant or breastfeeding women should not use this medication unless their doctor prescribes it and no safer alternative is available, and treatment is strictly necessary. In case of use, limit the dose and duration of treatment to a minimum.
Driving and using machines
The use of this medication does not affect the ability to drive and operate machines.
Follow the administration instructions of the medication contained in this package leaflet or as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist.
Bexidermil is a medication for exclusive external cutaneous use (on the skin).
The recommended dose is:
Apply a thin layer of the product to the painful or inflamed area 3 to 4 times a day.
It is advisable to perform the last application of the day before bedtime.
This medication is for cutaneous use, exclusively on intact skin. Do not ingest.
Wash your hands after each application.
Do not exceed the recommended dose of 3-4 applications per day.
You should consult a doctor if it worsens or does not improve after 7 days of treatment.
Use in children
This medication is for use in adolescents over 12 years of age.
If you use more Bexidermil 100 mg/g cream than you should
If you have applied more Bexidermil than you should, skin problems may occur.
Due to its external use (on the skin), intoxication is unlikely.
Accidental ingestion may cause nausea, vomiting, abdominal pain, restlessness, drowsiness, and vertigo. Patients with severe gastrointestinal or neurological symptoms should be observed and treated symptomatically. Do not induce vomiting.
In case of accidental ingestion, go immediately to a medical center or call the Toxicology Information Service, Telephone: 915 620 420, indicating the medication and the amount ingested.
Like all medications, this medication can cause side effects, although not everyone experiences them.
During the use of triethanolamine salicylate, the following side effects have been reported, whose frequency cannot be established with precision: cutaneous sensitization or allergic reactions in the application area that resolve when treatment is interrupted.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep out of sight and reach of children.
No special storage conditions are required.
Do not use Bexidermil after the expiration date shown on the packaging.
The expiration date is the last day of the month indicated.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This way, you will help protect the environment.
Composition of Bexidermil 100mg/g cream
The active ingredient is triethanolamine salicylate. Each gram of Bexidermil contains 100 mg of triethanolamine salicylate.
The other components (excipients) are: sorbic acid (E-200), propylene glycol (E-1520), stearyl alcohol, cetyl alcohol, sorbitan monooleate (E-491), polysorbate 60 (E-435), polysorbate 80, isopropyl myristate, butylhydroxyanisole (E-320), sodium edetate, camphor, menthol, and deionized water
Appearance of the product and package contents
Bexidermil 100 mg/g cream is a homogeneous white cream. It is presented in a 50g aluminum tube
Marketing authorization holder and manufacturer
Marketing authorization holder:
Isdin SA
Provençals, 33
08019 Barcelona
Spain
Manufacturer:
Kern Pharma, S.L.
Venus, 72 – Pol. Ind. Colón II
08228 Terrassa - Barcelona
Date of the last revision of this package leaflet: February 2022
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es